Chronic Refractory Gout Market, By Therapy Class (Uricase Therapies, IL-1 inhibitors, Adjunct Anti-inflammatories, and Next-generation Small Molecules), By Route of Administration, By Disease Burden, By Comorbidity Profile, By Care Setting, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4411
|
Published Date
October 2025
|
Pages
402
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Chronic Refractory Gout Market size was valued at US$ 1,804.25 Million in 2024, expanding at a CAGR of 10.23% from 2025 to 2032.
Chronic refractory gout is a severe form of gout where patients either do not respond adequately to standard urate-lowering treatments or cannot tolerate them. It is marked by persistently elevated uric acid levels, frequent painful flare-ups, and the development of tophi, which can cause joint and tissue damage. Managing this condition typically requires advanced therapies, such as uricase-based treatments or biologic agents, alongside comprehensive care for associated comorbidities to minimize complications and enhance patient quality of life. According to the World Health Organization, gout affects approximately 1-4% of the global population, with a rising prevalence driven by aging populations and increasing rates of metabolic disorders, prompting governments worldwide to prioritize improved management and treatment strategies for this chronic condition.
Chronic Refractory Gout Market- Market Dynamics
Rising Global Burden of Gout to Drive Market Demand
The rising global burden of gout is significantly increasing demand for advanced treatment options. In 2020, approximately 55.8 million people worldwide were affected by gout, with obesity and kidney dysfunction being major contributors to the disease’s disability impact. High body mass index (BMI) accounts for 34.3% of years lived with disability (YLDs) due to gout, while kidney dysfunction contributes 11.8%. Unfortunately, underdiagnosis of these comorbidities often leads to delayed or inadequate treatment, complicating disease management. In the United States, the Centers for Disease Control and Prevention (CDC) reports that over 1 in 7 adults suffer from chronic kidney disease (CKD), a key factor that worsens gout outcomes. Lifestyle interventions focused on weight management have proven effective in reducing gout severity and slowing disease progression. Furthermore, enhanced screening and early detection of CKD among gout patients can improve treatment strategies and patient prognosis, ultimately helping to reduce the burden of chronic refractory gout globally.
Moreover, ongoing government initiatives and increased awareness programs are playing a crucial role in addressing the challenges associated with gout management. For instance, several health agencies worldwide are prioritizing integrated care models that combine lifestyle modification with pharmacological therapies, aiming to improve patient adherence and outcomes. This holistic approach, supported by growing investments in research and development of novel therapeutics, is expected to transform the landscape of gout treatment and drive market growth in the coming years.
Chronic Refractory Gout Market- Segmentation Analysis:
The Global Chronic Refractory Gout Market is segmented on the basis of Therapy Class, Route of Administration, Disease Burden, Comorbidity Profile, Propulsion, Distribution Channel, and Region.
The chronic refractory gout market is segmented based on therapy class into uricase therapies, IL-1 inhibitors, adjunct anti-inflammatories, and next-generation small molecules. Among these, uricase therapies are expected to dominate the market during the forecast period due to their unique ability to rapidly and effectively reduce serum uric acid levels, especially in patients who do not respond to conventional treatments. This therapeutic advantage has led to increased adoption of uricase-based treatments. Government health agencies, such as the U.S. National Institutes of Health (NIH), actively fund research into innovative therapies for gout, promoting the development and accessibility of uricase treatments to address this unmet medical need.
The market is also divided by comorbidity profile into renal impairment and cardiovascular/metabolic conditions. The renal impairment segment is anticipated to hold the largest share, as chronic kidney disease is a common and serious complication in gout patients, limiting the use of traditional urate-lowering drugs. This creates a higher dependency on advanced therapies like uricase-based treatments, which are better suited for patients with compromised kidney function. Recognizing this challenge, health authorities such as the European Medicines Agency (EMA) have issued guidelines emphasizing the importance of specialized therapies for gout patients with renal impairment, driving demand for more effective and safer treatment options within this segment.
Chronic Refractory Gout Market- Geographical Insights
Geographically, North America leads the chronic refractory gout market due to a high disease burden and a well-established healthcare infrastructure. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 9.2 million adults in the United States suffer from gout, representing about 3.9% of the adult population. A significant portion of these patients develop chronic, treatment-resistant forms of the disease, which fuels demand for advanced therapies like pegloticase. The U.S. Food and Drug Administration (FDA) has prioritized the approval of biologics and novel urate-lowering agents to meet these unmet needs. Similarly, Europe has witnessed a rise in gout prevalence, with the UK’s National Health Service (NHS) reporting a significant increase in gout-related hospital admissions over the past decade. In the Asia-Pacific region, countries like Japan are also recognizing gout as an emerging health concern linked to lifestyle-related diseases, with the Ministry of Health, Labour and Welfare supporting initiatives to improve treatment access and patient outcomes, thereby expanding the regional market.
Chronic Refractory Gout Market- Competitive Landscape:
The rising prevalence of uncontrolled gout cases is driving companies to refine and advance treatment strategies. Industry players are focusing on developing biologics and uricase-based therapies that offer improved safety profiles and longer-lasting responses. Many are also exploring combination regimens with immunomodulators to reduce antibody formation and enhance therapeutic effectiveness. Strategic partnerships with research institutions, specialty clinics, and payers are being established to broaden patient access to these innovative treatments. Additionally, companies are investing in patient support programs, infusion services, and digital monitoring tools to improve treatment adherence and optimize long-term patient outcomes.
Recent Development:
- In March 2025, Shanton Pharma announced positive Phase 2b trial results for SAP-001 in patients with refractory gout, demonstrating nearly 100% target achievement compared to 10% with conventional therapy. The treatment showed sustained efficacy, strong safety, and durable effects over six months.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CHRONIC REFRACTORY GOUT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- LG Chem
- Jiangsu Hengrui Pharmaceuticals
- JW Group / Simcere
- Selecta / Cartesian Therapeutics
- Sobi (Swedish Orphan Biovitrum)
- Teijin America
- InventisBio
- Arthrosi Therapeutics
- Shanton Pharma
- Atom Bioscience
- Horizon Therapeutics / Amgen
- Nippon Chemiphar
- Protalix BioTherapeutics
- Arrowhead Pharmaceuticals
- Hinova Pharmaceuticals
- TaiwanJ Pharmaceuticals
- Cartesian Therapeutics
- Amgen
- Takeda Pharmaceutical Company
- AstraZeneca
- Others
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY THERAPY CLASS- MARKET ANALYSIS, 2019 - 2032
- Uricase Therapies
- IL-1 inhibitors
- Adjunct Anti-inflammatories
- Next-generation Small Molecules
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intravenous
- Subcutaneous
- Oral
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISEASE BURDEN- MARKET ANALYSIS, 2019 - 2032
- Tophaceous CRG
- Frequent Flares
- Erosive/structural damage
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY COMORBIDITY PROFILE- MARKET ANALYSIS, 2019 - 2032
- Renal Impairment
- Cardiovascular/Metabolic Conditions
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY CARE SETTING- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Specialty Rheumatology Clinics
- Infusion Centers
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Specialty Pharmacies
- Retail
GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Chronic Refractory Gout Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Chronic Refractory Gout Market Snippet by Therapy Class
2.1.2. Chronic Refractory Gout Market Snippet by Route of Administration
2.1.3. Chronic Refractory Gout Market Snippet by Disease Burden
2.1.4. Chronic Refractory Gout Market Snippet by Comorbidity Profile
2.1.5. Chronic Refractory Gout Market Snippet by Care Setting
2.1.6. Chronic Refractory Gout Market Snippet by Distribution Channel
2.1.7. Chronic Refractory Gout Market Snippet by Country
2.1.8. Chronic Refractory Gout Market Snippet by Region
2.2. Competitive Insights
3. Chronic Refractory Gout Key Market Trends
3.1. Chronic Refractory Gout Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Chronic Refractory Gout Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Chronic Refractory Gout Market Opportunities
3.4. Chronic Refractory Gout Market Future Trends
4. Chronic Refractory Gout Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Chronic Refractory Gout Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Chronic Refractory Gout Market Landscape
6.1. Chronic Refractory Gout Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Chronic Refractory Gout Market – By Therapy Class
7.1. Overview
7.1.1. Segment Share Analysis, By Therapy Class, 2023 & 2032 (%)
7.1.1.1. Uricase Therapies
7.1.1.2. IL-1 Inhibitors
7.1.1.3. Adjunct anti-inflammatories
7.1.1.4. Next-generation Small Molecules
8. Chronic Refractory Gout Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
8.1.2. Intravenous
8.1.3. Subcutaneous
8.1.4. Oral
Chronic Refractory Gout Market – By Disease Burden
8.2. Overview
8.2.1. Segment Share Analysis, By Disease Burden, 2023 & 2032 (%)
8.2.2. Tophaceous CRG
8.2.3. Frequent Flares
8.2.4. Erosive/Structural Damage
9. Chronic Refractory Gout Market – By Comorbidity Profile
9.1. Overview
9.1.1. Segment Share Analysis, By Comorbidity Profile, 2023 & 2032 (%)
9.1.2. Renal Impairment
9.1.3. Cardiovascular/Metabolic Conditions
10. Chronic Refractory Gout Market – By Care Setting
10.1. Overview
10.1.1. Segment Share Analysis, By Care Setting, 2023 & 2032 (%)
10.1.2. Hospitals
10.1.3. Specialty Rheumatology Clinics
10.1.4. Infusion Centers
11. Chronic Refractory Gout Market – By Distribution Channel
11.1. Overview
11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
11.1.2. Hospital Pharmacies
11.1.3. Specialty Pharmacies
11.1.4. Retail
12. Chronic Refractory Gout Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Chronic Refractory Gout Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.2.9. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.10. U.S.
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. U.S. Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.2.10.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.10.5. U.S. Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.2.10.6. U.S. Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.2.10.7. U.S. Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.2.10.8. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.10.9.
12.2.11. Canada
12.2.11.1. Overview
12.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.11.3. Canada Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.2.11.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.11.5. Canada Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.2.11.6. Canada Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.2.11.7. Canada Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.2.11.8. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.11.9.
12.3. Europe
12.3.1. Overview
12.3.2. Chronic Refractory Gout Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.9. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.10. Germany
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. Germany Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.10.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.10.5. Germany Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.10.6. Germany Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.10.7. Germany Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.10.8. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.11. Italy
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. Italy Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.11.5. Italy Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.11.6. Italy Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.11.7. Italy Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.11.8. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.12. United Kingdom
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. United Kingdom Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.12.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.12.5. United Kingdom Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.12.6. United Kingdom Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.12.7. United Kingdom Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.12.8. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.13. France
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. France Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.13.5. France Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.13.6. France Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.13.7. France Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.13.8. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.14. Russia
12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.2. Russia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.14.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.14.4. Russia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.14.5. Russia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.14.6. Russia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.14.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.15. Netherlands
12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.2. Netherlands Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.15.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.15.4. Netherlands Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.15.5. Netherlands Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.15.6. Netherlands Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.15.7. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.16. Sweden
12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.2. Sweden Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.16.4. Sweden Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.16.5. Sweden Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.16.6. Sweden Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.16.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.2. Poland Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.3.18.8. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Chronic Refractory Gout Key Manufacturers in Asia Pacific
12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. Asia Pacific Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.6. Asia Pacific Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.7. Asia Pacific Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.8. Asia Pacific Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.9. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.10.8. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.11. China
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. China Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.11.5. China Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.11.6. China Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.11.7. China Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.11.8. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.12. Japan
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. Japan Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.12.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.12.5. Japan Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.12.6. Japan Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.12.7. Japan Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.12.8. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.13. South Korea
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. South Korea Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.13.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.13.5. South Korea Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.13.6. South Korea Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.13.7. South Korea Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.13.8. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.14. Australia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Australia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.14.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.14.5. Australia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.14.6. Australia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.14.7. Australia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.14.8. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.15.8. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.16. Indonesia
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Indonesia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.16.5. Indonesia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.16.6. Indonesia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.16.7. Indonesia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.16.8. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.17. Philippines
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Philippines Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.17.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.17.5. Philippines Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.17.6. Philippines Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.17.7. Philippines Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.17.8. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.18. Rest of APAC
12.4.18.1. Overview
12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.18.3. Rest of APAC Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.18.5. Rest of APAC Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.4.18.6. Rest of APAC Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.4.18.7. Rest of APAC Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.4.18.8. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5. Latin America
12.5.1. Overview
12.5.2. Chronic Refractory Gout Key Manufacturers in Latin America
12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. Latin America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.6. Latin America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.5.7. Latin America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.5.8. Latin America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.5.9. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.10. Brazil
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Brazil Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.5.10.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.10.5. Brazil Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.5.10.6. Brazil Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.5.10.7. Brazil Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.5.10.8. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.11. Mexico
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Mexico Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.5.11.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.11.5. Mexico Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.5.11.6. Mexico Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.5.11.7. Mexico Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.5.11.8. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.12. Argentina
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Argentina Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.5.12.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.12.5. Argentina Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.5.12.6. Argentina Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.5.12.7. Argentina Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.5.12.8. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.13. Colombia
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Colombia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.5.13.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.13.5. Colombia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.5.13.6. Colombia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.5.13.7. Colombia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.5.13.8. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.14. Rest of LATAM
12.5.14.1. Overview
12.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.14.3. Rest of LATAM Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.5.14.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.14.5. Rest of LATAM Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.5.14.6. Rest of LATAM Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.5.14.7. Rest of LATAM Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.5.14.8. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Chronic Refractory Gout Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.9. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.10. Saudi Arabia
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. Saudi Arabia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.10.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.10.5. Saudi Arabia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.10.6. Saudi Arabia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.10.7. Saudi Arabia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.10.8. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.11. United Arab Emirates
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. United Arab Emirates Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.11.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.11.5. United Arab Emirates Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.11.6. United Arab Emirates Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.11.7. United Arab Emirates Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.11.8. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.12. Israel
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Israel Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.12.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.12.5. Israel Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.12.6. Israel Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.12.7. Israel Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.12.8. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.13. Turkey
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Turkey Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.13.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.13.5. Turkey Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.13.6. Turkey Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.13.7. Turkey Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.13.8. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.14. Algeria
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Algeria Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.14.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.14.5. Algeria Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.14.6. Algeria Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.14.7. Algeria Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.14.8. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.15. Egypt
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Egypt Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.15.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.15.5. Egypt Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.15.6. Egypt Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.15.7. Egypt Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.15.8. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.16. Rest of MEA
12.6.16.1. Overview
12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.16.3. Rest of MEA Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
12.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.16.5. Rest of MEA Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
12.6.16.6. Rest of MEA Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
12.6.16.7. Rest of MEA Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
12.6.16.8. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Chronic Refractory Gout Industry
13.1. Competitive Dashboard
13.1.1. Competitive Benchmarking
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. LG Chem
13.2.2. Jiangsu Hengrui Pharmaceuticals
13.2.3. JW Group / Simcere
13.2.4. Selecta / Cartesian Therapeutics
13.2.5. Sobi (Swedish Orphan Biovitrum)
13.2.6. Teijin America
13.2.7. InventisBio
13.2.8. Arthrosi Therapeutics
13.2.9. Shanton Pharma
13.2.10. Atom Bioscience
13.2.11. Horizon Therapeutics / Amgen
13.2.12. Nippon Chemiphar
13.2.13. Protalix BioTherapeutics
13.2.14. Arrowhead Pharmaceuticals
13.2.15. Hinova Pharmaceuticals
13.2.16. TaiwanJ Pharmaceuticals
13.2.17. Cartesian Therapeutics
13.2.18. Amgen
13.2.19. Takeda Pharmaceutical Company
13.2.20. AstraZeneca
13.2.21. Others
14. 360 Degree Analyst View
15. Ap
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
